The first is obviously what you just mentioned, which is the direct correlation between the reduction and the reduction of parenteral nutrition, the reduction in cost.
One way for investors to mitigate high correlation, RBC argues, is concentrating the number of stocks in a portfolio and sacrificing the potential cost of somewhat higher return variance.